Alcohol and drug interactions

Area of Science:

• Pharmacology
• Toxicology
• Public Health

Background:

• Alcohol use disorder is a major health concern in the Czech Republic, affecting morbidity, mortality, and pharmacotherapy.
• Risky alcohol consumption affects 15-18% of the population, with frequent, often overlooked, co-ingestion of drugs.
• Ethanol metabolism involves liver enzymes alcohol dehydrogenase (ADH) and cytochrome P450 2E1 (CYP2E1), with chronic use inducing CYP2E1.

Purpose of the Study:

• To review the complex interactions between alcohol and various drugs.
• To highlight the pharmacokinetic and pharmacodynamic consequences of alcohol-drug combinations.
• To identify populations at higher risk for adverse events.

Main Methods:

• Literature review of alcohol-drug interactions.
• Analysis of metabolic pathways involving ethanol and drug enzymes (ADH, CYP2E1).
• Examination of pharmacodynamic effects on the central nervous system (CNS) and other systems.

Main Results:

• Alcohol-drug interactions can be pharmacokinetic (altered absorption, enzyme induction/inhibition) or pharmacodynamic (potentiated toxicity, CNS depression, hypotension, hypoglycemia).
• Chronic alcohol use induces CYP2E1, potentially increasing toxic drug metabolite production.
• Specific risks include disulfiram-like reactions, increased neurotoxicity, seizures, and altered immune responses, especially with immunomodulatory therapies.

Conclusions:

• Elderly individuals with polypharmacy and altered pharmacokinetics face accumulated risks.
• Patients with liver cirrhosis and polymorbid elderly individuals are at the highest risk for severe alcohol-drug interactions.
• Further interaction studies are needed, considering limitations like liver injury and small sample sizes.